HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in high risk HER-2 high and intermediate expression breast cancers. Participants will have HER-2 driven IBC at least Stage IIIA with N2 following chemotherapy with/without trastuzumab or recurrence exclusive of new primary tumor but rendered NED. Mammogram, laboratory studies, CT, and leukapheresis will be performed, in addition to vaccine administration.
Epistemonikos ID: 4906710a78e47afc0cdfe9d5a63cac1a4f000ef7
First added on: May 11, 2024